CombiGene AB (publ) announced that the Company, after a thorough evaluation process, has chosen the Charles River Laboratories as a partner in CombiGene's and Zyneyro's peptide-based pain project, COZY01. Charles River - a highly respected, global provider of drug discovery and non-clinical development solutions - will perform the preclinical toxicology studies necessary to start the first in-human studies within the COZY01 project. In an evaluation of several contract research organizations (CROs), CombiGene has concluded that Charles River has the necessary resources and expertise to provide high quality studies adapted to the COZY01 program.

In addition, the Charles River Edinburgh site has provided valuable scientific support and advice throughout the evaluation process. Charles River has a global business with leading experience in drug development and has access to extensive expertise, which provides the required security for a company of CombiGene's size.